rss
Ann Rheum Dis 2003;62:1218-1220 doi:10.1136/ard.2003.014258
  • Concise report

Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study

  1. T I Temekonidis1,
  2. Y Alamanos2,
  3. S N Nikas1,
  4. D V Bougias1,
  5. A N Georgiadis1,
  6. P V Voulgari1,
  7. A A Drosos1
  1. 1Division of Rheumatology, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
  2. 2Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Greece
  1. Correspondence to:
    Professor A A Drosos
    Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece; adrososcc.uoi.gr
  • Accepted 29 July 2003

Abstract

Objective: To evaluate the efficacy and safety of long term infliximab therapy in patients with severe refractory ankylosing spondylitis (AS).

Patients and methods: Twenty five patients (24 male, 1 female; mean (SD) age 36.0 (10.5); disease duration 13.8 (8.5) years) with AS fulfilling the modified New York criteria for AS were investigated. Twenty two (88%) patients were HLA-B27 positive. All patients had active axial disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥30/100) and C reactive protein (CRP) ≥10 mg/l, despite adequate treatment. Intravenous infliximab (5 mg/kg) was given at weeks 0, 2, 6, and every eight weeks thereafter for 12 months. The primary end point was the reduction of the patient’s global assessment of pain (GAP) by >20% on a 100 mm visual analogue scale.

Results: GAP was reduced by >20% in 23 (92%) patients, by 50% in 21 (84%) patients, and by 70% in 13 (52%). The change in BASDAI and CRP from baseline was statistically significant. The treatment was well tolerated with minimal side effects. One patient dropped out owing to inefficacy and one stopped treatment owing to an allergic reaction.

Conclusion: This longer length study confirms the efficacy of infliximab and the good safety profile in patients with AS.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.